Both studies are designed to measure the patients' 72-week change in weight in response to three target doses of MariTide, a bispecific molecule designed to target gut hormone receptors (GLP-1 ...

Previously, in May 2024, the company dropped an early-stage obesity candidate, known as AMG 786, to go all in on MariTide. Little information was shared about the terminated small-molecule program ...

MariTide only needs to be taken once a month, and it's helped people lose up to 20% of their weight. Shares of this biotech are priced at a much lower premium than top GLP-1 drugmaker Eli Lilly.

Amgen on Wednesday said it has started two critical late-stage trials for its experimental weight loss injection MariTide, another step in its bid to enter the booming obesity drug market. " ...

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

But MariTide, which is Amgen's GLP-1 drug, only needs to be taken once a month. That can make it easier to stay on top of treatments. It may also result in fewer side effects, which is a key ...